Foamy virus vectors for HIV gene therapy

Area of Science:

• Gene Therapy
• Virology
• Immunology

Background:

• Highly active antiretroviral therapy (HAART) for HIV/AIDS is effective but lifelong, costly, and has side effects.
• Current retroviral gene therapy for HIV/AIDS is limited by inefficient gene delivery to hematopoietic stem cells (HSCs).

Purpose of the Study:

• To review the advantages of foamy virus (FV) vectors for anti-HIV gene therapy.
• To describe the preclinical development of FV vectors for treating HIV/AIDS.

Main Methods:

• Review of preclinical studies on foamy virus (FV) vectors.
• Analysis of FV vector characteristics, including safety, tropism, transgene capacity, and persistence.

Main Results:

• FV vectors offer an attractive safety profile and broad tropism.
• FV vectors demonstrate large transgene capacity and persistence in quiescent cells.
• FV vector titers are not reduced by anti-HIV transgenes, unlike lentivirus (LV) vectors.

Conclusions:

• Foamy virus (FV) vectors are a promising platform for developing effective and safe gene therapy for HIV/AIDS.
• FV vectors overcome key limitations of current gene delivery methods for HIV/AIDS treatment.